Recommended Dosage of Tofacitinib in Patients With UC1
*Use of tofacitinib in patients with severe hepatic impairment is not recommended.
ANC, absolute neutrophil count; BID, twice daily; CYP3A4, cytochrome P450 3A4; CYP2C19, cytochrome P450 2C19; UC, ulcerative colitis.
XELJANZ® (tofacitinib citrate) is a small molecule that selectively targets the JAK pathway
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022